Evidence map›Paper›PMID 41691070›Full record

ArticleScientific reports2026

Myelin-specific IL2 + T-cells are associated with last occurring relapse severity in relapsing-remitting multiple sclerosis.

Rina Zilkha-Falb, Tali Drori, Katya Shwartz, Michael Gurevich

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rina Zilkha-FalbMultiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.
Tali DroriMultiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.
Katya ShwartzMultiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.
Michael GurevichMultiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel. Michael.Gurevich@sheba.health.gov.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoreactive T-cells against myelin are implicated in multiple sclerosis (MS) however, the functional relevance of IL2-producing central memory T-cells and IFNɣ-producing effector T-cells have not been assessed. In this study we aimed to t investigate association of IL2 + and IFNγ + myelin reactive memory T-cells with MS severity and progression. Thirty relapsing–remitting MS (RRMS) patients and 32 age-matched healthy subjects (HS) were analyzed. Peripheral Blood Mononuclear Cells (PBMC) responses to proteolipid protein (PLP), myelin basic protein (MBP), and myelin oligodendrocyte glycoprotein (MOG) were assessed using IFNγ/IL2-FluoroSpot assay and correlated with disease severity and progression. Flow cytometry was performed to characterize central (CD45RO+CD62L+) and effector memory (CD45RO+CD62L-) T-cell subsets. Patients showed increased frequency and magnitude of IL2 responses to PLP compared with HS. Higher PLP-induced IL2 responses were in correlation with clinical severity of the last occurring relapse, including EDSS, EDSS change, and longer time from last occurring relapse (p < 0.05). Odds ratios (OR) confirmed associations between IL2-responses and last occurring relapse severity (OR range 5.3–22.5). Flow cytometry confirmed increase of central memory CD4 + and CD8 + T-cells in RRMS, whereas effector memory frequencies were unchanged. In RRMS, circulating PLP-reactive IL2 + central memory T-cells are linked to severity of last occurring relapse, representing an immunological imprint of recent disease activity rather than cumulative burden.

Indexed as

Interleukin-2Multiple Sclerosis, Relapsing-RemittingMyelin SheathT-LymphocytesAdultCase-Control StudiesFemaleHumansInterferon-gammaMaleMiddle AgedMyelin Basic ProteinMyelin-Oligodendrocyte GlycoproteinMyelin Proteolipid ProteinRecurrenceSeverity of Illness IndexIL2 protein, humanInterferon-gammaInterleukin-2Myelin Basic ProteinMyelin-Oligodendrocyte GlycoproteinMyelin Proteolipid Protein

Identifiers

PMID41691070
PMCPMC12992694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.